Therefore, the angiogenic effects of administration of OGD-PBMCs was assessed by immunofluorescence staining of the ischemic cortex at 28 days after cerebral ischemia using an antibody against the angiogenesis marker, i.e., CD31 (Fig. 5A). Here, PECAM1 is linked to brain ischemia.